Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer.

Literature DB >> 16985918

Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer.

Abstract

Decreased incidence of prostate cancer, improved therapies, and early detection have all have played some role in the decrease in prostate cancer mortality. The author discusses the development of improved methods of androgen deprivation therapy and demonstrates its significance in improved management of prostatic carcinoma.

Entities: Disease

Year: 2004 PMID： 16985918 PMCID： PMC1472894

Source DB: PubMed Journal: Rev Urol ISSN： 1523-6161

32 in total

1. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study.

Authors: A V Bono; F Pagano; R Montironi; F Zattoni; A Manganelli; F P Selvaggi; G Comeri; G Fiaccavento; S Guazzieri; C Selli; A Lembo; S Cosciani-Cunico; D Potenzoni; G Muto; L Diamanti; A Santinelli; R Mazzucchelli; T Prayer-Galletti
Journal: Urology Date: 2001-01 Impact factor: 2.649

2. Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma.

Authors: J G Klign; H J de Voogt; F H Schröder; F H de Jong
Journal: Lancet Date: 1985-08-31 Impact factor: 79.321

Review 3. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Authors: M Han; A W Partin; C R Pound; J I Epstein; P C Walsh
Journal: Urol Clin North Am Date: 2001-08 Impact factor: 2.241

4. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.

Authors: D P Byar; D K Corle
Journal: NCI Monogr Date: 1988

Review 5. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

Authors: I M Thompson; E J Zeidman; F R Rodriguez
Journal: J Urol Date: 1990-12 Impact factor: 7.450

6. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors: Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal: N Engl J Med Date: 2004-07-08 Impact factor: 91.245

7. Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors:
Journal: N Engl J Med Date: 1984-11-15 Impact factor: 91.245

8. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

Authors: William A See; Manfred P Wirth; David G McLeod; Peter Iversen; Ira Klimberg; Donald Gleason; Gerald Chodak; James Montie; Chris Tyrrell; D M A Wallace; Karl P J Delaere; Sigmund Vaage; Teuvo L J Tammela; Olavi Lukkarinen; Bo-Eric Persson; Kevin Carroll; Geert J C M Kolvenbag
Journal: J Urol Date: 2002-08 Impact factor: 7.450

9. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245

10. Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice.

Authors: W M van Weerden; G J van Steenbrugge; A van Kreuningen; E P Moerings; F H de Jong; F H Schröder
Journal: J Urol Date: 1991-03 Impact factor: 7.450

5 in total

Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer.

1. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study.

2. Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma.

Review 3. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

4. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.

Review 5. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

6. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

7. Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

8. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

9. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

10. Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice.

1. The evolving definition of advanced prostate cancer.

Review 2. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.

Review 3. Harnessing the potential of multimodal radiotherapy in prostate cancer.

4. Plasmid DNA vaccine coding eight repeats of gonadotrophin-releasing hormone induced atrophy of prostate in male mice.

5. Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer.